 |
|
Botulinum Toxin Type A for Treating Voice Tremor
Charles H. Adler, MD, PhD;
Stephen F. Bansberg, MD;
Joseph G. Hentz, MS;
Lorraine O. Ramig, PhD;
Eugene H. Buder, PhD;
Kristi Witt, MS;
Brian W. Edwards, MA;
Kari Krein-Jones, MS;
John N. Caviness, MD
Arch Neurol. 2004;61:1416-1420.
Background Voice tremor, like spasmodic dysphonia and other tremor disorders, may respond to botulinum toxin type A injections.
Objective To evaluate the safety and efficacy of botulinum toxin type A injections as treatment for voice tremor.
Design A randomized study of 3 doses of botulinum toxin type A with 6 weeks of follow-up.
Setting A single-site tertiary care center.
Participants and Methods Thirteen subjects (11 women, 2 men; mean age, 73 years) with voice tremor and no spasmodic dysphonia or head, mouth, jaw, or facial tremor were entered into this study. Patients received 1.25 U (n = 5), 2.5 U (n = 5), or 3.75 U (n = 3) of botulinum toxin type A in each vocal cord. All patients were evaluated at baseline and postinjection at weeks 2, 4, and 6.
Main Outcome Measures The primary outcome measure was the patient tremor rating scale, with secondary measures including patient-rated functional disability, response rating scale, independent randomized tremor ratings, and acoustical measures.
Results All patients at all dose levels noted an effect from the injection. The mean time to onset of effect was 2.3 days (range, 1-7 days). For all patients combined, mean tremor severity scale scores (rated by patients on a 5-point scale) improved 1.4 points at week 2, 1.6 points at week 4, and 1.7 points at week 6. Measures of functional disability, measures of the effect of injection, independent ratings of videotaped speech, and acoustic measures of tremor also showed improvement. The main adverse effects at all doses were breathiness and dysphagia.
Conclusion Voice tremor improves following injections of botulinum toxin type A.
Author Affiliations: Parkinson’s Disease and Movement Disorders Center, Department of Neurology (Drs Adler and Caviness, Mss Witt and Krein-Jones, and Mr Edwards), Department of Otorhinolaryngology (Dr Bansberg), Department of Biostatistics (Mr Hentz), Mayo Clinic Scottsdale, Scottsdale, Ariz; Department of Communication Disorders and Speech Science, University of Colorado at Boulder (Dr Ramig); School of Audiology and Speech-Language Pathology, University of Memphis, Memphis, Tenn (Dr Buder).
Financial Interest: Dr Adler has previously received research funding and honoraria from Allergan.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Simpson et al.
Neurology 2008;70:1699-1706.
ABSTRACT
| FULL TEXT
|
